Caribou Biosciences, Inc.
NASDAQ:CRBUBiotechnology
-$0.05 today
- Market cap
- $52.47M
- Beta
- 2.33
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.39
Volume 1.01M
Average 1.83M
CRBU Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Caribou Biosciences, Inc.NASDAQ: CRBU
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow declines year over year
Q1 FY2026 free cash flow of $27.06M (cash outflow) fell 28.4% year over year, in line with the -28.6% change in trailing-twelve-month free cash flow. Sequentially, it rose 31.3% from the prior quarter. Over 3 fiscal years it compounded at +4.9% a year.
Context
- Free cash flow amounted to 1006.8% of revenue in FY2025, down 441.1 pp from a year earlier.
- Free cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -28.4% holds above the trailing-twelve-month pace of -28.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (112.35M) USD
- Year-over-year change
- +22.4%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (112.35M) | +22.4% |
| FY2024 | 2024-12-31 | (144.71M) | -37.9% |
| FY2023 | 2023-12-31 | (104.9M) | -7.7% |
| FY2022 | 2022-12-31 | (97.42M) | -173.3% |
| FY2021 | 2021-12-31 | (35.64M) | — |
Free Cash Flow vs competitors
How CRBU compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -28.6% is the 8th highest of 11, against a peer median of -3.8%.
- Free cash flow amounts to 907.3% of revenue for CRBU, versus a peer median of 396.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $109.53M USD | -44.7% | -12.8% | — | |
| LTM Mar 2026 | $102.38M USD | +1.6% | +13.6% | 5078.2% | |
| LTM Mar 2026 | $101.64M USD | -28.6% | +4.9% | 907.3% | |
| FY2025 | €101.22M EUR | +17.3% | +30.6% | 2257.9% | |
| LTM Mar 2026 | $87.42M USD | -8.8% | — | 309.7% | |
| LTM Mar 2026 | $66.98M USD | +12.6% | -12.8% | 483.3% | |
| LTM Mar 2026 | $64.63M USD | -24.7% | -18.0% | 28725.3% | |
| LTM Mar 2026 | $61.75M USD | +125.4% | +72.7% | — | |
| LTM Mar 2026 | $55.08M USD | +1.1% | +18.3% | 168.3% | |
| LTM Mar 2026 | $43.78M USD | -58.6% | -13.4% | 261.8% | |
| LTM Mar 2026 | $9.61M USD | -88.3% | -28.2% | 13.9% | |
| Peer median (excluding CRBU) | — | -3.8% | -12.8% | 396.5% | |
Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (66.92M) | (99.42M) | (102.07M) | (149.11M) | (148.13M) |
| Depreciation & Amortization | 984K | 3.64M | 3.53M | 3.93M | 3.65M |
| Deferred Income Tax | 0 | (95K) | 0 | 0 | (548K) |
| Stock-Based Compensation | 3.45M | 11.72M | 13.75M | 16.71M | 12.68M |
| Change in Working Capital | 29.07M | (4.11M) | (7.32M) | (5.11M) | (484K) |
| Accounts Receivables | (2.96M) | 3.46M | 805K | 608K | 272K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.14M | (2.72M) | 1.82M | (354K) | 3.25M |
| Other Working Capital | 30.89M | (4.85M) | (9.94M) | (5.37M) | (4.01M) |
| Other Non-Cash Items | 904K | 9.02M | (1.18M) | (4.61M) | 21.84M |
| Operating Cash Flow | (32.52M) | (90.97M) | (93.29M) | (138.2M) | (110.99M) |
| Capital Expenditures | (3.12M) | (6.45M) | (11.61M) | (6.51M) | (1.36M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (173.28M) | (339.06M) | (394.76M) | (304.39M) | (150.37M) |
| Sales of Investments | 0 | 252.87M | 338.19M | 397.49M | 252.83M |
| Other Investing Activities | (1M) | (600K) | 0 | (1.61M) | 1.14M |
| Investing Cash Flow | (176.4M) | (93.25M) | (68.18M) | 86.61M | 102.24M |
| Debt Repayment | 1.03M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 321.02M | 2.13M | 152.72M | 15.19M | 4.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.55M | 0 | 1.58M | 1.53M | 0 |
| Financing Cash Flow | 433.43M | 2.13M | 154.3M | 16.72M | 4.82M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 224.51M | (182.08M) | (7.18M) | (34.87M) | (3.93M) |
| Free Cash Flow | (35.64M) | (97.42M) | (104.9M) | (144.71M) | (112.35M) |
Caribou Biosciences, Inc.
NASDAQ:CRBU
Intrinsic Alpha fair value
Locked
Current Price
$0.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.